TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences
Description
After three years of the SARS-CoV-2 pandemic, the search and availability of relatively low-cost benchtop therapeutics for people not at high risk for a severe disease are still ongoing. Although vaccines and new SARS-CoV-2 variants reduce the death